Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local bupivacaine versus placebo after minimally invasive sacroiliac joint fusion
NL-OMON51208Active, not recruiting
- Sponsor
- Zuyderland
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in sacroiliac joint disruption (SIJD) and None comparing Bupivacaine intra-articular injection with Placebo saline intra-articular injection (2 arms). Primary endpoint: Group difference in postoperative pain intensity. Started Jul 2021; status: active, not recruiting.
02
Drugs
bupivacaine
03
Conditions
sacroiliac joint disruption (SIJD)
Beyond the preview
Go deeper on NL-OMON51208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51208.